Research has focused on understanding the mechanisms responsible for this resistance, particularly in aggressive triple-negative breast cancer (TNBC), though resistance in HER2+ and ER+/HER2− subtypes has also been extensively investigated. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.